» Articles » PMID: 30707931

An Evaluation of the USEPA Proposed Approaches for Applying a Biologically Based Dose-response Model in a Risk Assessment for Perchlorate in Drinking Water

Overview
Publisher Elsevier
Specialties Pharmacology
Toxicology
Date 2019 Feb 2
PMID 30707931
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The United States Environmental Protection Agency's (USEPA) 2017 report, "Draft Report: Proposed Approaches to Inform the Derivation of a Maximum Contaminant Level Goal for Perchlorate in Drinking Water", proposes novel approaches for deriving a Maximum Contaminant Level Goal (MCLG) for perchlorate using a biologically-based dose-response (BBDR) model. The USEPA (2017) BBDR model extends previously peer-reviewed perchlorate models to describe the relationship between perchlorate exposure and thyroid hormone levels during early pregnancy. Our evaluation focuses on two key elements of the USEPA (2017) report: the plausibility of BBDR model revisions to describe control of thyroid hormone production in early pregnancy and the basis for linking BBDR model results to neurodevelopmental outcomes. While the USEPA (2017) BBDR model represents a valuable research tool, the lack of supporting data for many of the model assumptions and parameters calls into question the fitness of the extended BBDR model to support quantitative analyses for regulatory decisions on perchlorate in drinking water. Until more data can be developed to address uncertainties in the current BBDR model, USEPA should continue to rely on the RfD recommended by the NAS (USEPA, 2005) when considering further regulatory action.

Citing Articles

Exposure to perchlorate via drinking water from eight major water basins in China and its health risks across different age groups.

Lyu J, Chen Y, Zhang L, Yan X, Tudi M Sci Rep. 2025; 15(1):4580.

PMID: 39920287 PMC: 11806029. DOI: 10.1038/s41598-025-89057-2.


Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using , , and Human Biomonitoring Data.

McNally K, Sams C, Loizou G Front Pharmacol. 2019; 10:1394.

PMID: 31849656 PMC: 6897292. DOI: 10.3389/fphar.2019.01394.